


# **Statistics and Machine Learning Methods for Proteogenomic Data Analysis**


D. R. Mani  
Broad Institute

Northeastern University Short Course  
Computation and Statistics for Targeted Proteomics  
May 5, 2016


# Finding protein targets for Targeted Proteomics



Phase	Technologies	Analytes	Samples
<b>Discovery</b> Identify candidate	LC-MS/MS Extensive sample processing	1000	10
<b>Qualification</b> Confirm differential expression	Immuno: <b>ELISA, WB, IHC</b> Proteomics: MRM	5-100	10-50
<b>Verification</b> Proof-of-concept	Immuno: <b>ELISA</b> Proteomics: MRM	5-10	100
<b>Validation</b> Clinical assessment	ELISA	1-10	1000




# Unbiased biomarker discovery yields targets for Targeted Proteomics



Adapted from Rifai, et. al., *Nature Biotech.*, 2006.

# Unbiased discovery is increasingly Proteogenomic (or Multi-omic)

- Discovery efforts include multi-omic profiling
  - Omic profiling is getting cheaper
- Proteomic profiles are increasingly common
  - Smaller sample numbers due to higher cost
  - More input material needed



*Image Source: Goodacre, J. Exp. Bot 2005.*


# Proteogenomic analysis of Breast Cancer provides generalizable methods

- NIH CPTAC initiative to perform large-scale proteogenomic analysis of cancer samples
  - Breast Cancer—Broad Institute
  - Colon Cancer—Vanderbilt
  - Ovarian Cancer—Johns Hopkins/PNNL
- Presentation Goals:
  - Data analysis algorithms and toolkit for proteogenomics
    - Applied to breast cancer analysis, but generalizable
  - Generalized applicability to wide range of data sets
    - Potential use for targeted data analysis
      - » Some methods applicable, others need to be modified/applied with care




# Profiling of 105 TCGA samples produced largest proteomic dataset yet generated at Broad

- 105 BC Tumor Samples
  - PAM50 Subtypes: 18 Her2, 25 Basal, 29 Luminal A, 33 Luminal B
- Analyzed by iTRAQ-MS
  - Proteome + Phosphoproteome



# Sample processing


105 TCGA breast cancer samples



1 mg total protein per tumor

Internal reference: equal representation of basal, Her2 and Luminal A/B subtypes

Tumor-specific databases based on whole exome seq and RNA seq



Data analysis in Spectrum Mill

Clustering,  
Classification,  
Differential Analysis

# Sample processing: The basics

3 samples are included in each iTRAQ run. Each run also includes a **Common Reference** sample.

37 iTRAQ Runs  
105 samples

1 mg total protein per tumor

Internal reference: equal representation of basal, Her2 and Luminal A/B subtypes

Tumor-specific databases based on whole exome seq and RNA seq




Samples are **fractionated** for increased depth of coverage

[[enrichment]]


Phospho-proteome      Proteome

Spectrum Mill DATA output:  
Protein/peptide  
 $\log_2(\text{ratio to common reference})$




**Data Analysis Pipeline**

# Data Analysis Pipeline Overview



# Setup initiates automatic pipeline execution





- Tools:
  - bash
  - symbolic links
  - subversion (svn)
  - UGER  
(Univa grid engine for research)

- Unix shell script
- Create directories
- Copy input data files
- Assemble required code and additional data files
  - Code & data are versioned
- Execute all core analysis components
- Use Grid Engine for parallelization at multiple levels
  - Account for data dependencies

# Quality Control: Profile plots identify bimodal samples

- Bimodal samples are identified using (mixture) model-based clustering




- Tools:
  - Mclust (R)
- Bimodality is most likely due to poor sample quality

# Defining bimodal samples: Challenges

- Identify a metric that can separate bimodal/tailing samples from unimodal samples
  - Bimodality coefficient (too conservative—too many bimodals)
  - Dip statistic (too stringent—very few bimodal samples)
  - Measures of dispersion
    - IQR
    - Standard deviation (balanced metric)
- Classify new samples as unimodal/bimodal
  - Train classifier using single-shot (label-free) MS data
    - Use unimodal/bimodal designation as class vector
  - Apply to new samples as a QC check



# Normalization




- Each sample contains regulated and unregulated proteins.
  - Unregulated:  $\log_2(\text{ratio}) \sim 0$
  - Regulated: Extreme (+/-) ratios
- Normalize samples using only unregulated proteins.
- Unified method for both unimodal and bimodal samples

# Normalization Algorithm

## Using 2-component Gaussian mixture model

- Unimodal samples:
  - Find the mode  $M$  using kernel density estimation (Gaussian kernel with Shafer-Jones bandwidth)
  - Fit mixture model with mean for **both** components constrained to be equal to  $M$
  - Normalize (standardize) samples using mean  $M$  and smaller std. dev. from mixture model fit



# Normalization Algorithm

## Using 2-component Gaussian mixture model


- Bimodal samples:
  - Find the major mode M1 by kernel density estimation (Gaussian kernel with Shafer-Jones bandwidth)
  - Fit mixture model with **one** component mean constrained to M1
  - Normalize (standardize) samples using mean (M1) and resulting std. dev.
- Tools:
  - mixtools (R)
    - normalmixEM for EM estimation of mixture parameters ( $\mu, \sigma^2$ ) with constrained mean
  - Mclust (R)



# Normalization: Challenges


- Mixtools estimation is not robust, and can produce one-off results
  - Unrealistic mean and variance estimates
  - Large variation in estimates when re-fit
- Use mclust to assess parameter estimates from mixtools
  - Obtain approximate (unconstrained) estimate using mclust
  - Re-fit mixtools model multiple times to ensure repeatable parameter estimates
    - Must be close to mclust estimates

# Clustering for proteogenomic analysis



- Does the proteome capture intrinsic RNA-based classes?
- Does tumor heterogeneity invalidate genome-proteome comparisons?
- Define intrinsic proteome and phosphoproteome clusters
- How does phosphoproteome data cluster in pathway space?
  - Based on single-sample Gene Set Enrichment Analysis (ssGSEA)


# RNA-based PAM-50 clusters are captured in the proteome




- Tools: FANNY clustering (Kaufman & Rousseeuw, 1990)
  - cluster (R)

# FANNY

# Proteome and RNA samples co-cluster in the space of correlated genes






- Dataset: Combined RNA + proteome for 77 samples.
    - 4,291 proteins/genes with moderate to high correlation ( $R > 0.4$ )
  - Spearman correlation to measure sample similarity
  - AGNES hierarchical clustering
  - “Fanplot” to show co-clustering
    - 62/77 samples co-cluster



# AGNES

# (Intrinsic) Proteome Clusters


- 1,521 proteins with
  - No missing values
  - Standard deviation  $> 1.5$
- Consensus  $k$ -means clustering
  - 1000 bootstrap samples
  - $k=3,4,5,6$
- Assess cluster coherence
  - Visualization of consensus matrix
  - Consensus CDF/Delta-area plot
  - Silhouette distance




# Assessing cluster coherence

- Silhouette distance
- Consensus CDF
- Delta-area plot
- Tools:
  - cluster (R)
  - consensusClusterPlus (R)

# Proteome and Phosphoproteome Clusters





# Cell cycle, DNA-damage and immuno-regulatory gene sets are enriched in Basal-like tumors



# Phospho-pathway clustering


- Dataset: 5,914 phosphoproteins
  - Filtered Phosphoproteome data
    - Phosphosites with <81 missing values
    - Standard deviation > 0.5 across all samples
  - Phosphosite rolled-up to proteins using median ratio
  - Map phosphoproteins to genes
- Map samples to MSigDB pathways using ssGSEA
  - 908 curated pathways
- Consensus  $k$ -means clustering in pathway space
- Assess cluster coherence





**Phospho-pathway  
clustering identifies  
unique clusters**

# Association analysis via marker selection and GSEA



# Association Analysis and Marker Selection

- Collection of algorithms for
  - Identification of statistically significant differential markers
    - Multiclass
    - One-vs-all
  - Training of multiple classifiers
    - Partial Least Squares, Shrunken Centroids, Random Forests, Elastic Nets
    - Other algorithms can be easily added
  - Variable importance from classifiers for further prioritization of differential markers
    - Marker rank aggregation for final marker ranking
  - Class prediction for unknown/new samples
  - Visualization (heatmaps)
  - GSEA for pathway enrichment
  - EnrichmentMap for visualizing enriched pathways




# Rank Aggregation for Marker Ranking

- Perform Marker selection:
  - Identify statistically significant differential markers (SAM)
    - Multiclass
    - One-vs-all
  - Train multiple classifiers
    - Partial Least Squares, Shrunken Centroids, Random Forests, Elastic Nets
    - Other algorithms can be easily added
  - Rank markers using variable importance from classifiers
- Combine multiple rankings to a final rank
  - Robust rank aggregation (R. Kolde et. al., *Bioinformatics*, 2012)
    - Calculate final rank based on order statistics
    - Accommodates significant proportion of “noise” markers and occasional “low” ranks



# Linking copy number alteration and protein expression using LINCS (Library of Integrated Cellular Signatures)




# Approach

- Compare proteome profiles filtered by CNA TRANS correlations with LINCS functional knock-down data.
  - Genes with LINCS-enriched CIS effects are considered candidate driver genes
  - FDR for candidate driver genes is estimated using a permutation test



# CNA-protein correlations show CIS and many TRANS effects



TRANS effect “hot spots” at chromosomes 5q, 10p, 12, 16q, 17q, and 22q

- Correlate copy number (CN) data with proteome for all 60 million gene-protein pairs
- Plot statistically significant correlations (FDR < 0.05)
  - positive correlation
  - negative correlation
- Histogram shows percent of significant correlations at a CN locus
- Highlights “hot-spots” of TRANS-activity

## Can proteome profiles identify candidate genes driving response in copy number altered regions?

- A small number of key genes drive observed TRANS-effects
- To identify candidate genes:  
Correlate proteome profiles of CN altered samples with gene knock-down mRNA profiles
- CN amplification negatively correlated to knock down profile and/or CN deletion positively correlated to knock down profile  
    → candidate causal gene




# Leveraging large scale perturbation datasets to identify candidate causal genes in CNA regions

## Library of Integrated Cellular Signatures (LINCS) aka The Connectivity Map (CMAP)

PROCESSING OF BROAD LINCS DATA


<http://www.lincscloud.org>



- LINCS Functional knock-down profiles on ~3,800 genes:
  - Multiple hairpins per gene knock-down
  - 1000 landmark genes measured on Luminex assay
  - Complete profile (~22,000 genes) calculated by inference
  - Includes ~20,000 drug perturbagens. Total ~476,000 mRNA profiles

# Use LINCS to identify key genes driving response to copy number alterations: STEP 1


CNA\_status  
 CNA\_amp  
 CNA\_del  
 CNA\_neutral



- Identify samples with deletion [ $\log(\text{CN}) < -0.3$ ], neutral and amplification [ $\log(\text{CN}) > 0.3$ ] CNA for a given gene
- Extract protein expression for genes with significant TRANS-effects (FDR < 0.05).


# Use LINCS to identify key genes driving response to copy number alterations: STEP 2

CNA\_status  
 CNA\_amp  
 CNA\_del  
 CNA\_neutral




- Summarize expression in CNA\_DEL, CNA\_AMP and CNA\_NEUTRAL groups
  - Median expression for each trans-gene

## Use LINCS to identify key genes driving response to copy number alterations: STEP 3



- Determine up and down regulated genes in CNA\_DEL and CNA\_AMP (in comparison to CNA\_NEUTRAL expression)

# Use LINCS to identify key genes driving response to copy number alterations: STEP 4



- Query LINCS using CNA\_AMP/DEL gene sets
  - Convert CNA\_AMP/DEL gene sets to Affymetrix IDs
  - Run LINCS enrichment test on ~240,000 “gold” consensus signatures (CGS).
  - Extract “CIS-enriched” gene knock downs:
    - Enriched gene knock downs include CIS gene
      - Correct direction of correlation (+ve for CNA\_DEL, -ve for CNA\_AMP)
    - $|mean\_rankpt4| > 90$ 
      - Mean percentile in 4 cell lines > 90
  - Extract and analyze z-scores for CIS-enriched genes

# Calculate Permutation-based FDR

1. For each of the genes input to the LINCS enrichment test, generate a random permutation as follows:
  - Let gene G have  $N_g$  TRANS genes
  - From the list of all genes, randomly select  $N_g$  genes (without replacement)
2. Run LINCS enrichment for this permuted dataset
3. Determine  $FP_i$ , the number of “candidate driver genes” from the random dataset.
4. Repeat Steps 1-3  $R$  times.
5. Calculate FDR as mid point of 95% Score CI assuming Poisson distribution with small rate ( $\lambda \approx 0$ ) and small  $R$  ( $R=6$ ).

$$FDR = E\left(\frac{\# FP}{\# P}\right) = \frac{E(\# FP)}{\# P} = \frac{\overline{FP} + 1.96^2 / (2R)}{\# P} \quad \text{where } \overline{FP} = \frac{1}{R} \sum_{i=1}^R FP_i$$


$$\text{95\% Score CI for } E(\# FP) = \overline{FP} + 1.96^2 / (2R) \pm 1.96 \frac{\sqrt{4\overline{FP} + 1.96^2 / R}}{\sqrt{4R}}$$

# Results


- Input gene sets:
  - $\geq 15$  tumors with  $|CNA| > 0.3$
  - Gene must be on CMAP KD list
  - # TRANS genes  $\geq 20$
  - Total genes tested: 502
- 20 CIS-enriched candidate genes
  - Level I: 10 genes
    - Enriched in both CNA\_AMP and CNA\_DEL
  - Level II: 10 genes
    - Enriched in either CNA\_AMP or CNA\_DEL

	✧ Level I	✧ Level II
CETN3	FBXL20	
SKP1	ERBB2	
SNX2	USP6NL	
FBXO7		
TERF2IP	ARHGEF12	
WIPF2	MRPL12	
YAP1	RAB21	
RB1	EP300	
USP7	CPNE3	
DHPS	PLCB3	
FDR=0.049 [0.003, 0.094]	UBE3C	
		FDR=0.305 [0.225, 0.385]


# SKP1 and CETN3 are new candidate causal genes for 5q CNA TRANS effects



- 20 candidate causal genes were identified
- ERBB2 serves as a positive control
- CNA/Protein CIS effects are more indicative for a CMAP connection to TRANS regulated genes than CNA/RNA CIS effects



# LINCS data: Knock-down of SKP1 and CETN3 increases EGFR, YES1 and DAPK3 expression



# CMAP programming interface for large-scale queries

- LINCS Cloud Compute server with command line interface
  - Run large-scale batch queries using a Grid Engine
- Programming interface
  - R, Python, Matlab
  - For accessing and manipulating LINCS data and results
- Web-based API
  - For accessing and querying metadata
    - Perturbations and perturbagens
    - Signatures
    - Measured and inferred genes
- HDF5 (hierarchical data format) for storing data
- Mongo DB for metadata

# Challenges and Implementation

# Summary

- Automated pipeline enables high throughput analysis of CPTAC data
  - Reproducible and documented process
  - Version controlled
  - Generalizable to other projects
  - Easy comparison of alternatives
  - Effective use of parallelism
- Marker selection and classification can be used for any analysis
  - Automated
  - Multiple ML methods

# Acknowledgments

## BROAD INSTITUTE

- **Steve Carr**
- **Karl Clauer**
- **Michael Gillette**
- **Jana Qiao**
- Lauren Tang
- **Philipp Mertins**
- **D R Mani**
- Karsten Krug
- Eric Kuhn
- Filip Mundt
- Corey Flynn
- Jacob Asiedu
- Aravind Subramaniyan

## FHCRC

- Amanda Paulovich
- Jeffrey Whiteaker
- Pei Wang
- Sean Wang
- Chenwei Lin
- Ping Yan
- Yuzheng Zhang

## NCI STAFF

- Emily Boja
- Mehdi Mesri
- Rob Rivers
- Chris Kinsinger
- **Henry Rodriguez**

## WASHINGTON U./ NYU/UNC/ VANDERBILT

- Sherri Davies
- **Matthew Ellis**
- **Reid Townsend**
- **Li Ding**
- Song Cao
- Michael McLellan
- Kuan-lin Huang
- Venkata Yellapa
- **David Fenyö**
- **Kelly Ruggles**
- **Chuck Perou**
- Michael Gatza
- **Bing Zhang**
- Jing Wang

**FUNDING:** National Cancer Institute